Cancer Center

CTRC commences enrollment in Phase 2 trial of REOLYSIN combination for SCC lung cancer

CTRC commences enrollment in Phase 2 trial of REOLYSIN combination for SCC lung cancer
A virus that destroys cancer cells but leaves normal cells unharmed may offer hope to those affected by squamous cell carcinoma of the lungs (SCC lung cancer), according to investigators from the Cancer Therapy & Research Center (CTRC) at the University of Texas Health Science Center at San Antonio. The CTRC has started patient enrollment in a US Phase 2 clinical trial using intravenous …

Terramed Alliance News Safe To Treat HER2-positive Breast Cancer

Standard adjuvant treatment for HER2-positive breast cancer patients, following primary surgery for their cancer, is Trastuzumab (Herceptin)–typically used in combination with chemotherapy. However, a new study by researchers at Fox Chase Cancer Center reports that it may be safe to treat these patients with both Trastuzumab and adjuvant radiation therapy.

The study will be presented at the annual meeting of the American Society for Radiation Oncology (ASTRO).

Benefits of breast cancer screening outweigh the harms, study shows

Benefits of breast cancer screening outweigh the harms, study shows
Routine breast cancer screening saves the lives of two women for every one who receives unnecessary treatment, a study suggests today.

Cancer Center

CTRC commences enrollment in Phase 2 trial of REOLYSIN combination for SCC lung cancer

Related posts

Terramed Alliance News Safe To Treat HER2-positive Breast Cancer

Related posts

Benefits of breast cancer screening outweigh the harms, study shows

Related posts